The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study için istatistikler
Toplam ziyaret
| views | |
|---|---|
| The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study | 1 |
Aylık toplam ziyaret
| views | |
|---|---|
| Nisan 2025 | 0 |
| Mayıs 2025 | 0 |
| Haziran 2025 | 0 |
| Temmuz 2025 | 0 |
| Ağustos 2025 | 0 |
| Eylül 2025 | 0 |
| Ekim 2025 | 0 |
